M. Gil-Martin

M. Gil-Martin, B. Pardo, M. Barretina-Ginesta, 2020, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

P. LoRusso, P. Ott, J. Bendell, 2021, Journal for ImmunoTherapy of Cancer.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

W. Mason, J. Machiels, B. Melichar, 2022, ESMO open.

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

R. Dienstmann, A. Gil-Moreno, J. Piulats, 2019, Gynecologic oncology.

A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.

R. Salazar, R. Alemany, M. Cascalló, 2019, Human gene therapy.

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.

I. Lowy, K. Papadopoulos, I. Braña, 2020, Gynecologic oncology.

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

R. Salazar, J. Bellmunt, C. Montagut, 2013, Investigational New Drugs.

Cancer Therapy : Preclinical Lurbinectedin ( PM 01183 ) , a New DNA Minor Groove Binder , Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

M. Esteller, M. Pujana, G. Capellá, 2012 .

Lurbinectedin ( PM 01183 ) , a New DNA Minor Groove Binder , Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

M. Esteller, M. Pujana, G. Capellá, 2012 .

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

B. Monk, A. Tinker, A. Oza, 2017 .

Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain.

J. Puig-Barberá, M. Gil-Martin, S. Márquez-Calderón, 1997, Journal of epidemiology and community health.

Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.

B. Mellado, J. García-Donas, J. Pérez-Gracia, 2022, Clinical genitourinary cancer.

Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

M. Esteller, M. Pujana, G. Capellá, 2012, Clinical Cancer Research.

Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer

E. Winer, J. Berlin, J. Baselga, 2015 .

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

F. Rojo, A. Pandiella, A. Urruticoechea, 2017, Oncotarget.

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

J. Desai, Robert W. Hsieh, K. Morrissey, 2020 .

798P A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001

J. García-Donas, J. Piulats, A. Oaknin, 2021, Annals of Oncology.

Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer

M. Campone, A. Urruticoechea, J. Beck, 2012 .

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

J. Berlin, J. Baselga, D. Juric, 2013 .

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery

Andrea Plaja, J. Piulats, A. Esteve, 2023, International journal of molecular sciences.

Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).

T. Pluard, F. Ademuyiwa, I. Mayer, 2017 .

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

F. Hodi, Philippe Bédard, Z. Wainberg, 2023, JAMA oncology.

Molecular approaches for classifying endometrial carcinoma.

R. Sanz-Pamplona, X. Matías-Guiu, A. Velasco, 2017, Gynecologic oncology.

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

S. Westin, E. Van Nieuwenhuysen, S. Nishio, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.

J. Machiels, R. Salazar, S. Rottey, 2014 .

Phase I study of pazopanib in combination with interferon alfa in patients with advanced renal cell carcinoma (RCC) and other primary tumors: A Spanish Oncology Genitourinary Group (SOGUG) study.

J. García-Donas, I. Durán, M. Gil-Martin, 2014 .